|Bid||6.01 x 1300|
|Ask||6.05 x 800|
|Day's Range||5.34 - 6.09|
|52 Week Range||1.55 - 16.32|
|Beta (5Y Monthly)||0.61|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
Akers and Premas Biotech are three steps into a four-step plan that could lead to clinical trials of a vaccine candidate.
Akers Biosciences Inc., a South Jersey medical device company that recently joined the race to develop a COVID-19 vaccine, plans to raise $4.6 million in a public stock sale. The Thorofare-based company is selling 766,667 shares of its common stock at a purchase price of $6.00 per share, according to documents filed with the Securities and Exchange Commission. Last month, Akers entered into an in-licensing and product development deal for a coronavirus vaccine candidate under development by Premas Biotech.